cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 635 Documents
 60   61   62   63   64 
Case Series of Preserving Ankle Stability After Giant Cell Tumor Resection in the Lateral Malleolus: Role of Fibular Head Autograft Mujaddid Idulhaq; Andre Young; Fajar Baskoro Gardjito
Indonesian Journal of Cancer Vol. 20 No. 2 (2026): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i2.1504

Abstract

Background: Giant Cell Tumor (GCT) is a non-metastatic bone tumor known for its local aggressiveness and recurrence risk. While commonly affecting the knee and distal radius, involvement of the distal fibula, particularly the lateral malleolus, is extremely rare. Standard surgical approaches may jeopardize joint mechanics in this critical load-bearing region. This case series highlights the application of ipsilateral autologous fibular head grafting to restore ankle stability following tumor resection. We aim to offer a practical reference for biological reconstruction in managing uncommon GCTs of the lateral malleolus.Case Presentation: Two female patients, aged 20 and 14 years old, presented with progressively enlarging, painful right lateral ankle masses. Both patients underwent Magnetic Resonance Imaging (MRI), revealing a well-defined lytic lesion with fluid-fluid levels and cortical thinning consistent with GCT. They underwent wide resection or reoperation followed by fibular head autograft, and one-third tubular plate (OTP) fixation. At 3-year and 6-month follow-up, both showed no recurrence and regained excellent function, with Musculoskeletal Tumor Society Score (MSTS) and American Orthopaedic Foot & Ankle Score (AOFAS) of 28/30, 94/100, and 26/30, 92/100, respectively.Conclusions: This case series supports the use of fibular head autografting as a joint-preserving solution following lateral malleolus GCT resection. Our findings provide preliminary evidence for a biologically favourable and functionally effective method applicable to similar rare presentations.
Initial Presentation of Acute Promyelocytic Leukemia as Orbital Myeloid Sarcoma Resembling Neuroblastom Donytra Arby Wardhana; Lydia Friska Malau; Usi Sukorini; Tiarasari Nurjunievi
Indonesian Journal of Cancer Vol. 20 No. 2 (2026): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i2.1512

Abstract

Background: Myeloid sarcoma (MS) is a rare extramedullary tumor composed of myeloblasts or immature myeloid cells. It is often associated with acute promyelocytic leukemia (APL), which is a subtype of acute myeloid leukemia (AML), but rarely presents as the initial manifestation of the disease, particularly in children. Diagnosing MS is challenging due to its rarity and clinical resemblance to other malignancies. Early identification and proper diagnostic evaluation are crucial for accurate diagnosis and timely intervention. Case Presentation: We report a 2-year-old girl presenting with a history of a cranial mass and bilateral orbital involvement, initially suspected as neuroblastoma. Laboratory findings revealed anemia, leukocytosis with increased immature granulocytes. Bone marrow aspirate analysis demonstrated 40% promyelocytes, consistent with APL. Fine needle aspiration biopsy (FNAB) of the mandibular lesion showed malignant cells, and immunocytochemical staining was positive for myeloperoxidase (MPO), confirming the diagnosis of MS. The patient was treated with all trans retinoic acid (ATRA) and the chemotherapy agent methotrexate combined with daunorubicin, leading to a favorable response.Conclusions: This case highlights the importance of considering myeloid sarcoma in the differential diagnosis of orbital masses in children, especially when accompanied by hematologic abnormalities. Early recognition and appropriate diagnostic workup, including bone marrow analysis and immunocytochemistry, are essential to establish the diagnosis of APL with extramedullary involvement and to initiate prompt, targeted therapy.
Low-Dose Pazopanib in Metastatic Renal Cell Carcinoma: A Retrospective Survival Study Febriyani Febriyani; Rachmat Budi Santoso; Edward Usfie Harahap; Ikhlas Arief Bramono
Indonesian Journal of Cancer Vol. 20 No. 2 (2026): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i2.1541

Abstract

Background: Pazopanib is approved as a first-line targeted therapy for metastatic renal cell carcinoma (mRCC), typically initiated at 800 mg once daily. However, maintaining this standard dose is often challenging due to patients’ poor general condition and treatment-related adverse effects. Few studies have explored whether a reduced dose could provide comparable clinical benefits with improved tolerability. This study aims to investigate the clinical survival outcomes of an initial low dose (400 mg) of Pazopanib in mRCC patients.Methods: This retrospective pilot study evaluated mRCC patients between 2019 and 2024 who were treated with an initial 400 mg Pazopanib and followed by escalation to 800 mg (if possible) at a national cancer referral hospital. If patients could not tolerate escalation dose, they received the low dose throughout treatment. Demographic data, adverse effects, and survival outcomes were collected. Radiographic progression-free survival (rPFS) and overall survival (OS) were estimated using the Kaplan-Meier method.Results: Forty-three patients (aged 21—77 years) were included, with 67.9% being male. Most patients (48.8%) had a single site of metastasis, with the liver being the most common. After a mean follow-up of 15.1 (± 7.1) months, 18 patients (41.9%) had died. The median rPFS was 14.6 months (11.6—17.6), and the median OS was 23.5 months (19.3—27.7). Only 3 patients (6.97%) discontinued treatment due to adverse effects. While 27.9% experienced no adverse events, the most common symptoms were nausea and vomiting (25.6%).Conclusions: Initiating treatment with 400 mg Pazopanib in mRCC patients may offer acceptable survival outcomes with good tolerability and compliance. In the future, this low-dose strategy could serve as a feasible alternative for patients at risk of poor tolerance to standard dosing.
Cross-Cultural Adaptation and Psychometric Evaluation of The Indonesian EORTC QLQ-FA12 In Breast Cancer Patients Achmad Fauji; Mayang Damayanty; Tjut Jessy Fiolina; Jusnimar Jusnimar; Yati Afiyanti
Indonesian Journal of Cancer Vol. 20 No. 2 (2026): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i2.1576

Abstract

Background: Cancer-related fatigue is a significant concern for breast cancer patients undergoing chemotherapy, yet Indonesia lacks a culturally validated tool to assess. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Fatige-12 (EORTC QLQ-FA12), which measures physical, emotional, and cognitive fatigue, is available only in English. This study aims to evaluate the validity and reliability of the Indonesian version of the EORTC QLQ-FA12.Methods: A cross-sectional methodological study applied forward-backward translation following Beaton’s guidelines. Pretesting and validation involved 30 and 70 patients, respectively. Psychometric evaluation included content validity, internal consistency, exploratory factor analysis (EFA), and confirmatory factor analysis (CFA). Results: The scale showed strong content validity index (CVI = 0.917) and internal consistency (alpha = 0.905). Although EFA suggested statistical clustering of items, CFA supported the theoretical multidimensional structure of the original instrument. Model fit indices were acceptable (Goodness-of-Fit Index (GFI) = 0.952, Comparative Fit Index (CFI) = 0.930, Tucker Lewis Index (TLI) = 0.904, Standardized Root Mean Square Residual (SRMR) = 0.056), while Root Mean Square Error of Approximation (RMSEA) = 0.098 indicated moderate approximation error. Factor loading ranged from 0.23 to 0.91.Conclusions: The Indonesian EORTC QLQ-FA12 demonstrates satisfactory reliability and acceptable construct validity, preserving the multidimensional fatigue framework. The instrument is suitable for clinical and research assessment of cancer-related fatigue in Indonesian breast cancer patients
Complex Pediatric Neuroblastoma Presenting With Superior Vena Cava Syndrome, Tumor Lysis, and Massive Pleural Effusion Maya Novariza; Sri Mulatsih, MD, PhD; Pudjo Hagung Widjajanto; Alexandra Pangarso; Dito Pondra Dharma; Aulia Suluk Brilliant Sumpono; Yunanto Kurnia; Clements Nicodhemus Garuda Nagara
Indonesian Journal of Cancer Vol. 20 No. 2 (2026): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v20i2.1637

Abstract

Background: The simultaneous presence of superior vena cava syndrome, tumor lysis syndrome, massive pleural effusion, and metabolic syndrome in a child with mediastinal neuroblastoma is exceedingly rare and sparsely described in the literature. The concurrent occurrence of superior vena cava syndrome (SVCS), tumor lysis syndrome (TLS), massive pleural effusion, and metabolic syndrome in a pediatric patient is exceedingly rare and poses significant diagnostic and therapeutic challenges. This case report highlights a rare and urgent clinical scenario involving these overlapping conditions.Case Presentation: An 8-year-old girl presented with shortness of breath, facial swelling, cough, and a neck lump. Imaging revealed a large mediastinal mass with massive right pleural effusion. Laboratory findings supported the diagnosis of TLS and metabolic syndrome in the context of obesity. Histopathology confirmed the differentiation of neuroblastoma. The patient was managed with steroids, chemotherapy, drainage, and supportive care, including metabolic syndrome assessment and nutritional interventions. Conclusions: This case emphasizes the importance of early recognition and multidisciplinary management of complex pediatric oncology emergencies. SVCS, TLS, and massive pleural effusion may co-occur in rare mediastinal neuroblastomas, especially in children with obesity and metabolic syndrome. Prompt recognition and integrated multidisciplinary care are essential to improve outcomes in complex pediatric oncology emergencies.

Page 64 of 64 | Total Record : 635

 60   61   62   63   64 

Filter by Year

2007 2026


Reset
Filter By Issues
All Issue Vol. 20 No. 2 (2026): June Vol 20, No 1 (2026): March Vol 19, No 4 (2025): December Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue